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Objective: This study is to investigate the clinical therapeutic effects and safety of treating  mild or 
moderate depression with somatic symptoms with electroacupuncture combined with Fluoxetine. Methods: 
95 cases of mild or moderate depression with somatic symptoms were randomly divided into a Fluoxetine 
group, and an electroacupuncture plus Fluoxetine group. Hamilton Depression Scale (HAMD) was used for 
the assessment of clinical therapeutic effects and Treatment Emergent Symptom Scale (TESS) was used for 
assessment of adverse reactions. Results: The total effective rate was 77.27% in the Fluoxetine group and 
78.26% in the electroacupuncture plus Fluoxetine group, showing no statistically significant difference 
between these two groups (P>0.05). However, the treatment took effect after two weeks in the 
electroacupuncture plus Fluoxetine group but after four weeks in Fluoxetine group. During this time, a better 
therapeutic effect on depression with mild or moderate somatic symptoms was found in the 
electroacupuncture plus Fluoxetine group, which also had fewer adverse reactions than the Fluoxetine group. 
Conclusion: Electroacupuncture combined with Fluoxetine takes effect faster for relieving the somatic 
symptoms with fewer adverse reactions. It is worth popularizing clinically.   
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Depression is a common emotional mental disorder 
characterized by significant and long-lasting 
depressed emotion, anhedonia or fatigue, with 
somatic symptoms such as discomfort and declining 
ability. Most patients go to general hospitals for 
treatment with complaints of somatic symptoms. 
Somatization is a phenomenon by which psychic 
complaints are expressed as somatic symptoms, and 
by which personal psychological processes as well as 
various problems of social groups are interpreted, 
expressed and experienced as somatic symptoms. It is 
a modus in which patients deal with psychological 
and social difficulties. Somatic symptoms include 
insomnia, headache, dizziness, fatigue, poor appetite, 
breath holding and/or unfixed chronic pain (including 
gastrointestinal pain, precordial pain, headache or 
backache, which cannot be relieved with analgetics).1
Although the occurrence and duration of these 
symptoms are closely correlated with the  
unhappiness, difficulties or conflicts,  patients often 
deny the existence of psychological factors and 
attribute the depressed emotions to physical 
problems.2,3 Long-term symptomatic treatment 
without obvious efficacy may delay the pathogenetic 
condition and lead to chronic diseases. 
For mild to moderate depression, medical inter- 
vention is not the only treatment. The clinical 
application and research into using traditional 
medicine, including acupuncture therapy, for 
treatment of depression has been carried out for many 
years and has resulted in some marked achieve- 
ments.4-6 According to the internationally recognized 
criteria for diagnosis and therapeutic effect, the 
clinical efficacy, effect-onset and safety of the 
treatment have been observed in two different ways, 
electroacupuncture plus Fluoxetine and Fluoxetine 
alone, to determine the different therapeutic effects 
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for depression, in order to determine the optimal 
therapeutic regimen for depression with somatic 
symptoms.7,8   
CLINICAL MATERIALS 
General Data 
This study was approved by the Hospital Ethics 
Committee. All 95 cases in this series were in- and 
outpatients from Department of Neurology and 
Department of Psychology in the PLA General 
Hospital. They were randomly divided into a 
Fluoxetine group and an electroacupuncture plus 
Fluoxetine group. The general data is shown in Table 
1.   
Table 1. General Data in Both the Fluoxetine Group and the Electroacupuncture Plus Fluoxetine Group ( x fs)
Sex SeverityGroup Cases
Male Female
Age  
(year)
Course 
(month)
HAMD Score 
(before treatment) Mild Moderate
Fluoxetine 47 19 28 37±11.22 17.9±4.8 25.2±3.5 22 25
Fluoxetine + Acupuncture 48 17 31 38±10.17 16.2±8.4 22.9±4.1 23 25
The general data was statistically compared between 
the two groups of patients. There were no significant 
differences in sex (df=1, Ȥ2=0.4314, P=0.806), age 
(df=73, t=0.67, P=0.5157), course of disease (df=73, 
t=0.6458, P=0.62), HAMD score before treatment 
(df=73, t=1.40, P=0.1669), and severity of disease 
(df=1, Ȥ2=0.48, P=0.8059), indicating that the 
baseline data were comparable between the two 
groups.  
Diagnostic Criteria  
The diagnosis of depression in the study was 
consistent with the diagnostic criteria ICD-10 for 
mild or moderate psycholepsy.9 The patients with two 
typical symptoms and two other core symptoms were 
diagnosed as having mild depression; patients with 
two typical symptoms and three other core symptoms 
were diagnosed as havibg moderate depression. 
Standard for severity10: According to the Hamilton 
Depression Scale (HAMD) and the cut-off score by 
Davis JM, 20–26 of HAMD score was considered as 
mild depression, and 27–34 was considered as 
moderate depression.  
Standard for the accompanying somatic symptoms: 
At least two of the following symptoms were 
included: 1) sleep disorder, 2) headache or dizziness, 
3) gastrointestinal symptoms, 4) cardiovascular 
symptoms, 5) chronic pain, and 6) general malaise. 
Inclusive Criteria   
1) The patients were 18–60 years met the above 
diagnostic criteria; 2)  with a HAMD score for 
somatic symptoms between 20–34; 3) with no serious, 
organic brain diseases and somatic disease history; 4) 
with no history of mental disorder; 5) voluntarily 
signed the informed consent. 
Exclusive Criteria 
1) Patients who had schizophrenia or other mental 
disorders; 2) complications with organic diseases 
such as tumors and central nervous system diseases; 
3) pregnant women, lactating women, or women who 
were pregnant during the treatment; 4) patients with 
psychiatric symptoms; 5) patients with severe 
depression evidenced bya HAMD score 35 and 
suicidal tendencies; 6) patients who were intolerant 
or hypersensitive to Fluoxetine, or who had severe 
adverse reactions in the past.  
METHODS 
For Fluoxetine Group 
A 5-HT antidepressant Fluoxetine was used (trade 
name: Fluoxetine; Common name: Fluoxertine 
hydrochloride capsule, produced by Suzhou Eli Lilly 
and Company of the United States; Specification: 20
mg/pill). It was orally taken 20 mg/day for six weeks.  
For Electroacupuncture Plus Fluoxetine Group 
Patients were treated with oral Fluoxetine and by 
electroacupuncture. Baihui (GV 20) and Yintang 
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(EX-HN3) were connected to G68052-I electro- 
acupuncture treatment device. The output wave was 
continuous at a frequency of 120–250 per minutes, 
the intensity was set according to the patient’s 
tolerance, and each session of treatment lasted 30 
minutes. Meanwhile, conventional body acupuncture 
was adopted: for stagnation of liver qi, Taichong (LR 
3) and Hegu (LI 4) were selected; for stagnated qi
transforming into fire, Xingjian (LR 2) and Xiaxi 
(GB 43) were selected; for melancholy disturbing the 
mind, the sleeping point, Shenmen (HT 7), and 
Neiguan (PC 6) were selected; for deficiency of both 
the heart and spleen, Sanyinjiao (SP 6) and Zusanli
(ST 36) were selected; for excessive fire due to 
deficiency of yin, Taixi (KI 3) and Zhaohai (KI 6) 
were selected. The patients were treated once a day, 
with a one-day interval in a week, for six weeks. 
Criteria for Therapeutic Effects  
The patients were assessed with HAMD by two 
doctors of psychology who had rich clinical 
experience and were not responsible for the 
treatment,. The doctors were requested to achieve 
98%–100% consistency in scoring the results of the 
assessments.. 
The therapeutic effects were evaluated by examining 
changes in the HAMD scores expressed as the “score 
reducing rate”. The assessment was done before 
treatment and once a week during the treatment.  
The score-reducing rate = (total score before 
treatment ˉ total score after treatment) / total score 
before treatment× 100%;  
The score-reducing rate >75% was considered to be 
clinically controlled, 50%–75% markedly relieved, 
25%–49% improved, and <25% failed. 
The General HAMD Scoring Assessment  
The general HAMD scoring assessment includes  
seven categories of factors. Four of these were 
observed in this study: somatic symptoms, sleep 
disorders, depressive retardation and cognitive 
disturbance. The somatic symptoms consisted of 5 
items, which were psychic anxiety, somatic anxiety, 
gastrointestinal symptoms, hypochondriasis and 
insight. The sleep disorders consisted of 3 items, i.e. 
difficulty in falling asleep, light sleep and early 
awakening. The depressive retardation consists of 4 
items, including depressive emotions, fatigue/ 
inability to work, intestinal blockage and sexual 
symptoms. The cognitive disturbance consists of 6 
items, including self-accusation, suicide, agitation, 
depersonalization and derealization, paranoid 
symptoms and obsessive compulsive symptoms. For 
a better understanding of the characteristics of 
depression, the factor analysis can accurately reflect 
the changes of target symptoms before and after the 
treatment.  
Each of the factor scores equals the total score of the 
factor / the number of items. The assessment was 
carried out before and after the treatment.  
Assessment of the Adverse Effects with the TESS 
Scale 
The Treatment Emergent Symptom Scale (TESS) was 
formulated by NIMH in the United States in 1973. It 
involves the most complete items and widest 
coverage among similar scales, including the 
common adverse signs and symptoms as well as 
several laboratory results. It is used frequently in 
WHO collaborative research.  
The original TESS requests assessment of each 
symptom in terms of the severity, the medicine- 
symptom relationship and the measures adopted. The 
symptoms clearly related to the medical treatment 
were assessed in the “severity” column. The score 
was 0 for no symptoms; one for the light or 
suspicious symptoms; two for the mild symptoms 
that did not affect functioning but were somewhat 
troublesome, if there was ambiguous evidence for the 
existence of the symptoms according to complaints 
from patients; three for moderate symptoms that 
affected functioning to a certain degree, but with no 
serious impacts on daily life, although the patients 
may feel uncomfortable or uneasy, and the presence 
of symptoms can be observed; and four for severe 
symptoms that seriously affected the patient’s daily 
life and activities.  
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Blood pressure, blood and urine routine, liver 
function and electrocardiograms were examined for 
the patients of both groups, including those who gave 
up the treatment because of serious adverse effects 
induced by Fluoxetine, at the end of the second, 
fourth and sixth week of the treatment. Assessments 
were made based on physical examinations and 
laboratory reports. And the family members of 
patients were asked to provide additional information. 
The total score of “severity” was calculated for each 
patient to get the average value for each group. 
Statistical Analysis 
The patients who dropped out of the study due to the 
adverse effects of Fluoxetine were not assessed with 
HAMD, but they were assessed and analyzed with 
TESS.   
Measurement Data  
The paired-sample t test was used for intragroup 
comparison; and the independent sample t test was 
used for intergroup comparison. 
Numerical Data  
The single ordinal Chi-square test (Row Mean Score 
Differ) was used.
RESULTS 
In the Fluoxetine group, dizziness and postural 
hypotension appeared in one patient one week after 
taking Fluoxetine, and panic and pyknosphygmia 
showed by EKG were found in another patient four 
weeks after taking Fluoxetine. The treatment was 
terminated for these patients because of the serious 
adverse effects. In addition, one patient’s emotions 
were stimulated by the death of his mother, and he 
was hospitalized for integrated therapy because the 
illness was aggravated to severe depression. In the 
acupuncture plus Fluoxetine group, the treatment was 
terminated for one patient because of sexual dys- 
function, and for another patient with drug- induced 
dysuria. These 5 cases were not included in the 
statistical analysis, but the 4 patients with serious 
drug-induced adverse effects were assessed by TESS.
The Total Therapeutic Effects  
The total therapeutic effects of the two groups are 
shown in Table 2.
Table 2. Total Therapeutic Effects in the Fluoxetine Group and the Electroacupuncture Plus Fluoxetine Group 
Group Number of 
Subjects
Clinically 
Controlled 
N (%)
Significantly 
Relieved 
N (%)
Improved 
N (%)
Failed 
N (%)
Total 
Effective 
Rate (%)
Fluoxetine 44 6 (13.63) 17 (38.64) 11 (25.00) 10 (22.73) 77.27
Fluoxetine+Acupuncture 46 8 (17.39) 18 (39.13) 10 (21.74) 10 (21.74) 78.26
The data in table 2 was compared by Row Mean 
Scores Differ (df=1, Ȥ2=0.05, P=0.83). There was no 
significant difference between the Fluoxetine group 
and the acupuncture plus Fluoxetine group.  
The HAMD Scoring Assessment 
The HAMD scores of the two groups are shown in 
Table 3.
Table 3. The HAMD Scores for the Fluoxetine Group and the Electroacupuncture Plus Fluoxetine Group  
Before and After Treatment ( x fs) 
Analysis Group Baseline Endpoint Reduction Rate 
Df t P
Fluoxetine 25.1f3.7 12.7f5.5 50.8f17.6 33 20.47 <0.0001
Fluoxetine+acupuncture 23.8f4.0 10.f5.1 56.8f15.2 35 24.44 <0.0001
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Table 3 shows the intragroup comparison of the 
HAMD scores in the two groups before and after 
treatment, with statistically significant differences 
between baseline and endpoint scores indicating 
marked therapeutic effects in both groups.  
The independent samples t test was used for inter- 
group comparison of the score-reducing rate between 
two groups, with no significant difference indicating 
a similar therapeutic effect in both the Fluoxetine 
group and electroacupuncture plus Fluoxetine group.  
HAMD Scores of the Factors  
The HAMD factor scores between the two groups 
before and after treatment are shown in Table 4.  
Table 4. Comparison of the HAMD Factor Scores Between Two Groups ( x fs) 
Analysis Factor Group Baseline Endpoint 
Df t P 
   68 8.33 0.002 
Fluoxetine 5.5f0.3 3.5f0.3 33 1.42 0.21 
Somatic symptoms 
Fluoxetine+ acupuncture 5.5f0.3 2.2f0.2 35 11.98 0.003 
   68 8.59 0.007 
Fluoxetine 4.9f0.1 2.8f0.2 33 2.07 0.04 
Sleep disorder 
Fluoxetine+ acupuncture 4.9f0.1 1.8f0.2 35 19.93 <0.0001
   68 1.3 0.26 
Fluoxetine 6.8f0.3 3.3f0.3 33 2.39 0.03 
Retardation 
Fluoxetine+ acupuncture 6.7f0.4 3.4f0.3 35 2.05 0.04 
   68 1.04 0.34 
Fluoxetine 4.4f0.2 3.1f0.2 33 1.07 0.37 
Cognitive disturbance
Fluoxetine+ acupuncture 4.4f0.2 3.3f0.2 35 0.96 0.43 
Table 4 suggests significant differences in the factor 
scores for depressive retardation and sleep disorder 
before and after treatment in the Fluoxetine group,
and in the factor scores for somatic symptoms, 
depressive retardation and sleep disorder before and 
after treatment in the electroacupuncture plus 
Fluoxetine group. Symptoms that failed to show 
significant alleviation included the somatic symptoms 
and cognitive disturbance in Fluoxetine group, and 
the cognitive disturbance in electroacupuncture plus 
Fluoxetine group. The intergroup comparison showed 
a significant difference in the therapeutic effect for 
the somatic symptoms between the two groups.  
Assessment for the Clinical Effect–Start Time
Table 5 shows that in the Fluoxetine group there were 
significant differences in HAMD scores starting from 
the fourth week of treatment; and that there were 
significant differences in HAMD scores starting from 
the second week of treatment in the electro- 
acupuncture plus Fluoxetine group.  
Table 5. Comparison of the HAMD Scores Between 
the Two Groups During Treatment ( x fs) 
 Fluoxetine Fluoxetine+acupuncture
Baseline 25.1f3.7 23.8f4.0 
Week 1 23.3f4.3 20.3f3.9 
Week 2 22.7f4.6 16.9*f4.3 
Week 3 20.9f4.7 15.3f4.7 
Week 4 17.6*f5.6 13.7f5.3 
Week 5 14.2f6.3 11.8f5.9 
Week 6 12.7f5.5 10.7f5.1 
Note: *P<0.05 
Assessment for Adverse Effects  
The comparison of TESS scores between the two 
groups is shown in Table 6. 
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Table 6. TESS Scores for the Fluoxetine Group and the Electroacupuncture Plus Fluoxetine Group ( x fs)
Analysis (df=68)Fluoxetine Fluoxetine + acupuncture
t P
Week 2 12.3f5.3 8.3f1.7 2.31 0.0196
Week 4 11.2f3.3     5.7f1.3 3.85 <0.0001
Week 6  9.9f2.3 4.2f1.6 3.97 <0.0001
From Table 6, a significant difference can be found 
between the two groups in the second week of 
treatment, and there are markedly significant 
differences in the 4th and 6th week of treatment. 
As the treatments continued, the TESS scores 
gradually declined in both groups. On the one hand, 
four patients suffered from so severe adverse effects 
that the treatment and the assessment had to be 
terminated. On the other hand, the decline may be 
related to the mitigating effect of electroacupuncture 
in the electroacupuncture plus Fluoxetine group.  
DISCUSSION 
Like most of the selective serotonin reuptake 
inhibitors (SSRIs), slow onset is one of the defects of 
Fluoxetine, which may show effect 2–4 weeks after 
medication. It is one of the main reasons for low 
compliance among patients. Therefore, to increase 
the compliance for antidepressant medicines, there is 
an urgent demand for new medication with faster, 
more stable and better long-term effects. 11-15
Depression is a disease manifested by both somatic 
and mental symptoms, which should be treated by 
expectant medications. For example, to alleviate the 
somatic symptoms, sedative hypnotics, anticoagulant 
medicines and antipsychotic medicines should be 
added. However, the combined use of medications 
may cause a risk of medicine interaction, and lead to 
a reciprocal causative vicious cycle. 2, 11-12, 15-17
For patients who suffer depression accompanied by 
somatic symptoms, the adverse effect of Fluoxetine is 
another problem.18 The adverse effects may increase 
the psychological burden of patients, and lower the 
compliance for treatment. Psychotherapy can directly 
explore the psychogenic factors, so it is effective for 
relieving the psychological symptoms, but it is not 
effective for patients with mainly somatic symptoms 
who are reluctant to expose their psychological 
factors.  
The electroacupuncture treatment may take effect 
within two weeks, and may show immediate effects 
for somatic symptoms in some patients. Therefore, 
the combined use of acupuncture and medicines for 
depression patients cannot only reduce their suffering, 
but also increase their trust in the treatment.19-21
And during the acupuncture treatment, the patients 
may have more opportunities to communicate with 
the doctors and other patients, which may enhance 
their confidence, and play a  role in their health 
rehabilitation.15  
The present observations showed that both treatments 
were effective for mild and moderate depression. 
However, Fluoxetine had a stronger effect for 
improving physical fatigue, while electro- 
acupuncture showed a better effect for relieving  
sleep and appetite disorders. Electroacupuncture can 
improve some of the somatic symptoms of depression, 
especially the gastrointestinal symptoms, chronic 
pain and sleep disorders. 13, 19-21 And electro- 
acupuncture can directly treat the somatic symptoms, 
without the need for additional medications, without 
physical and mental dependence and without 
withdrawal symptoms, but with good compliance. 
For patients suffering from depression with serious 
somatic symptoms and for elderly patients and 
patients in poor physical condition, acupuncture 
combined with medicine would be their first choice.  
In this study, the treatment with Fluoxetine was 
terminated in 4 patients because of serious adverse 
effects. And the majority of patients had different 
degrees of adverse effects in the process of taking 
Fluoxetine. However, during electroacupuncture 
treatment, there were no adverse effects except the 
normal needling sensations. Electroacupuncture plus 
Fluoxetine could reduce the adverse effects caused by 
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antidepressants, such as headache, dry mouth, nausea, 
vomiting, anorexia, diarrhea, constipation, and low 
blood pressure. The therapeutic efficacy was felt after 
2 weeks, and became more obvious four weeks after 
the treatment.   
To summarize, clinical practice has shown that we 
can combine the TCM syndrome differentiation with 
the disease diagnosis of Western medicine. The 
prescription of points for electroacupuncture 
treatment of depression should vary according to 
different symptoms. Electroacupuncture therapy is 
applicable for patients who cannot tolerate  anti- 
depressant medications, for patients with aggravated 
somatic symptoms after medical treatment and for 
elderly depressed patients.22  
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